Signal active
Investment Firm
Overview
Baxter International Inc. develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions.
The company operates through three segments: BioScience, Medication Delivery, and Renal.
Baxter International Inc. has collaborations with HHD LLC, DEKA Products Limited Partnership, and DEKA Research and Development Corp. for the development of a home hemodialysis machine. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors offices, clinical and medical research laboratories, and patients at home under physician supervision.
The company was founded in 1931 and is headquartered in Deerfield, Illinois.
Highlights
1931
Biotechnology
10001+
13
6
4
Early Stage Venture, Late Stage Venture, Seed
N/A
Location
Deerfield, Illinois, United States, North America
Contact Information
Social
Profile Resume
Baxter International, established in 1931 and headquartered in United States, North America., specializes in Early Stage Venture, Late Stage Venture, Seed investments across Biotechnology, Health Care, Medical, Biopharma, Therapeutics, Financial Services, Venture Capital, Finance, Asset Management, Life Science. The organization boasts a portfolio of 13 investments, with an average round size of $22.1M and 4 successful exits. Their recent investments include Gliknik, Naurex, Adams Street Partners, Latterell Venture Partners, Genesys Capital. The highest investment round they participated in was $24.1B. Among their most notable exits are Gliknik and Naurex. Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
13
1
6
4
Investments
13
Annouced Date | Organization Name | Industry | Money Raised |
---|---|---|---|
May 01, 2020 | Ayogo Health | Information Services | 7.5M |
Nov 21, 2021 | Walela | Health Care | 237.5K |
Jan 10, 2022 | - | - | 110.0M |
Mar 15, 2022 | NovaXS Biotech | Biotechnology | 846.5K |
Exits
4
Funding Timeline
13
1
0
Funding Rounds
13
Baxter International has raised 13 rounds. Their latest funding was raised on Mar 15, 2022 from a Seed Round - NovaXS Biotech round.
Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
---|---|---|---|---|
May 01, 2020 | Series B - Ayogo Health | - | 7.5M | - |
Nov 21, 2021 | Seed Round - Walela | - | 237.5K | - |
Jan 10, 2022 | Venture Round - Medically Home | - | 110.0M | - |
Mar 15, 2022 | Seed Round - NovaXS Biotech | - | 846.5K | - |
Investors
2
Baxter International is funded by 2 investor(s). German Federal Ministry of Education and Research Kantor is the most recent investors.
Investor Name | Lead Investor | Funding Round | Money Raised |
---|---|---|---|
- | No | Post-IPO Debt - Baxter International | 1680.0M |
German Federal Ministry of Education and Research | Yes | Grant - Baxter International | 1.8M |
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
Annouced Date | Fund Name | Money Raised |
---|---|---|
May 10, 2013 | OTPPLESS | 1.0M |
May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
News
Aug 20, 2024
PE Hub - Baxter International to divest kidney care unit to Carlyle for $3.8bn
News
Aug 20, 2024
Reuters - Carlyle to buy Baxter's kidney-care spinoff Vantive for $3.8 billion
News
Aug 20, 2024
Crain's Chicago Business - Baxter raises profit projections as it mulls kidney care divesture
News
Aug 13, 2024
PE Hub - Baxter International to divest kidney care unit to Carlyle for $3.8bn
News
Jul 01, 2024
BizTimes - Milwaukee Business News - Baxter International will close its Milwaukee facility
News
May 08, 2024
Yahoo Finance - Baxter International First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags